These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15303523)

  • 1. The relevance of intellectual property laws to reimportation.
    Wagner WJ
    Manag Care; 2004 Jun; 13(6 Suppl):20-2; discussion 33-4, 41-2. PubMed ID: 15303523
    [No Abstract]   [Full Text] [Related]  

  • 2. United States prescription drug crisis. Reimportation of Canadian prescription drugs is not the answer.
    Martin J
    J Leg Med; 2006 Dec; 27(4):477-92. PubMed ID: 17162683
    [No Abstract]   [Full Text] [Related]  

  • 3. The World Health Organization's prequalification program and its potential effect on data exclusivity laws.
    Childs DW
    Food Drug Law J; 2005; 60(1):79-97. PubMed ID: 15940855
    [No Abstract]   [Full Text] [Related]  

  • 4. Rx Depot to stop importing drugs from Canada.
    FDA Consum; 2004; 38(6):3. PubMed ID: 15675009
    [No Abstract]   [Full Text] [Related]  

  • 5. Canada moves to shut Rx pipeline.
    Boehm C
    Revolution (Oakl); 2005; 6(4):4-5. PubMed ID: 16187566
    [No Abstract]   [Full Text] [Related]  

  • 6. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
    Correa CM
    Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
    [No Abstract]   [Full Text] [Related]  

  • 7. An overview of pharmaceutical cocrystals as intellectual property.
    Trask AV
    Mol Pharm; 2007; 4(3):301-9. PubMed ID: 17477544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical reimportation: the European experience--what the United States can expect.
    Golec JH; Vernon JA
    Manag Care; 2004 Jun; 13(6 Suppl):26-9; discussion 33-4, 41-2. PubMed ID: 15303525
    [No Abstract]   [Full Text] [Related]  

  • 9. International pharmaceutical expenditure differentials: why?
    Dickson M
    Manag Care; 2004 Mar; 13(3 Suppl):3-6. PubMed ID: 15074161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A counselor's dose of preventive medicine.
    Redlick D; Kapner V
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE51-3. PubMed ID: 12089589
    [No Abstract]   [Full Text] [Related]  

  • 11. Commercializing intellectual property for healthcare businesses.
    Penner MD; Holbeche KE
    Health Law Can; 2010 Feb; 30(3):143-5. PubMed ID: 20422809
    [No Abstract]   [Full Text] [Related]  

  • 12. The consumer and reimportation.
    Gross DJ
    Manag Care; 2004 Mar; 13(3 Suppl):43-4. PubMed ID: 15074173
    [No Abstract]   [Full Text] [Related]  

  • 13. TRIPs revisited.
    Ford N
    Br J Gen Pract; 2001 Nov; 51(472):948. PubMed ID: 11761222
    [No Abstract]   [Full Text] [Related]  

  • 14. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 15. Intellectual property and access to ART: unwise choice of terminology.
    Stallman R
    PLoS Med; 2006 Nov; 3(11):e509; author reply e510. PubMed ID: 17132062
    [No Abstract]   [Full Text] [Related]  

  • 16. Sleep less in Seattle.
    Lancet; 1999 Dec; 354(9194):1917. PubMed ID: 10622287
    [No Abstract]   [Full Text] [Related]  

  • 17. Intellectual property. Plants and intellectual property: an international appraisal.
    Koo B; Nottenburg C; Pardey PG
    Science; 2004 Nov; 306(5700):1295-7. PubMed ID: 15550646
    [No Abstract]   [Full Text] [Related]  

  • 18. Integrating the intellectual property value chain.
    Barrett B; Crawford D
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE43-6. PubMed ID: 12089587
    [No Abstract]   [Full Text] [Related]  

  • 19. Status of legislation on pharmaceutical reimportation.
    Palumbo FB
    Manag Care; 2004 Jun; 13(6 Suppl):3-6; discussion 12-3, 41-2. PubMed ID: 15303518
    [No Abstract]   [Full Text] [Related]  

  • 20. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.